Research map: Mineralocorticoid receptor overactivation in heart failure with preserved ejection fraction

Back to the article

Papers in this map

  1. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction · John J.V. McMurray · 2019 · 7146 citations · Cited by this paper
  2. Disrupted erythrocyte S1P-eNOS axis promotes hypoxia, hypertension and fibrosis in obstructive sleep apnoea-hypopnoea syndrome · 2026 · Related
  3. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure · Milton Packer · 2020 · 5221 citations · Cited by this paper
  4. Gut microbe-generated metabolite trimethylamine N-oxide and risk of abdominal aortic aneurysm: a cohort study · 2026 · Related
  5. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction · Bertram Pitt · 2003 · 4965 citations · Cited by this paper
  6. Rethinking antiplatelet evidence through the lens of ethnicity · 2026 · Related
  7. Empagliflozin in Heart Failure with a Preserved Ejection Fraction · Stefan D. Anker · 2021 · 4865 citations · Cited by this paper
  8. Right aortic arch and double arch: current clinical challenges · 2026 · Related
  9. A Novel Paradigm for Heart Failure With Preserved Ejection Fraction · Walter J. Paulus · 2013 · 3564 citations · Cited by this paper
  10. Weekly Journal Scan: Discontinuation due to adverse events varies across antihypertensive regimens · 2026 · Related
  11. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes · George L. Bakris · 2020 · 2886 citations · Cited by this paper
  12. Epidemiological studies impacting clinical practice · 2026 · Related
  13. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction · Scott David Solomon · 2022 · 2871 citations · Cited by this paper
  14. AMPK/USP10 loop activation of ACE2: implications for pulmonary hypertension · 2026 · Related
  15. Spironolactone for Heart Failure with Preserved Ejection Fraction · Bertram Pitt · 2014 · 2809 citations · Cited by this paper
  16. The safety of low lipoprotein(a): a story not yet fully told · 2026 · Related
  17. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction · Scott David Solomon · 2019 · 2428 citations · Cited by this paper
  18. Spotlight on EHRA 2026: illuminating arrhythmia management · 2026 · Related
  19. Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction · Barry M. Massie · 2008 · 1967 citations · Cited by this paper
  20. Unmasking Hormonal Mechanisms of Hypertension in Obesity · 2026 · Related
  21. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes · Bertram Pitt · 2021 · 1742 citations · Cited by this paper
  22. Lifetime Risk for Developing Congestive Heart Failure · Donald M. Lloyd‐Jones · 2002 · 1619 citations · Cited by this paper
  23. Epidemiology of heart failure with preserved ejection fraction · Shannon M. Dunlay · 2017 · 1568 citations · Cited by this paper
  24. Prospective Study of Obstructive Sleep Apnea and Incident Coronary Heart Disease and Heart Failure · Daniel J. Gottlieb · 2010 · 1563 citations · Cited by this paper
  25. Diastolic Heart Failure — Abnormalities in Active Relaxation and Passive Stiffness of the Left Ventricle · Michael R. Zile · 2004 · 1556 citations · Cited by this paper
  26. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association · Yerem Yeghiazarians · 2021 · 1418 citations · Cited by this paper
  27. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction · Paul W. Armstrong · 2020 · 1349 citations · Cited by this paper
  28. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis · Rajiv Agarwal · 2021 · 1298 citations · Cited by this paper
  29. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial · Bryan Williams · 2015 · 1295 citations · Cited by this paper
  30. Triggering and amplifying pathways of regulation of insulin secretion by glucose. · Jean‐Claude Henquin · 2000 · 1218 citations · Cited by this paper
  31. Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction · Masaru Obokata · 2017 · 1162 citations · Cited by this paper
  32. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. · Karl B Swedberg · 1990 · 1157 citations · Cited by this paper
  33. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction · Kevin Shah · 2017 · 1123 citations · Cited by this paper
  34. Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial · Marc Alan Pfeffer · 2014 · 1068 citations · Cited by this paper
  35. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis · Silvia Monticone · 2017 · 1060 citations · Cited by this paper
  36. Epidemiology and One-Year Outcomes in Patients With Chronic Heart Failure and Preserved, Mid-Range and Reduced Ejection Fraction: An Analysis of The ESC Heart Failure Long-Term Registry · Ovidiu Chioncel · 2017 · 927 citations · Cited by this paper
  37. Atrial Fibrillation Begets Heart Failure and Vice Versa · Rajalakshmi Santhanakrishnan · 2016 · 889 citations · Cited by this paper
  38. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction · Scott David Solomon · 2024 · 845 citations · Cited by this paper
  39. Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction · Frank Edelmann · 2013 · 749 citations · Cited by this paper

Source: OpenAlex (CC0)